A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening - PubMed (original) (raw)
Multicenter Study
. 1995 Feb 15;273(7):535-41.
Affiliations
- PMID: 7837387
Multicenter Study
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening
D Shattuck-Eidens et al. JAMA. 1995.
Abstract
Objectives: To report the initial experience of an international group of investigators in identifying mutations in the BRCA1 breast and ovarian cancer susceptibility gene, to assess the spectrum of such mutations in samples from patients with different family histories of cancer, and to determine the frequency of recurrent mutations.
Design: Nine laboratories in North America and the United Kingdom tested for BRCA1 mutations in DNA samples obtained from a total of 372 unrelated patients with breast or ovarian cancer largely chosen from high-risk families. Three of these laboratories also analyzed a total of 714 additional samples from breast or ovarian cancer cases, including 557 unselected for family history, for two specific mutations that had been found to recur in familial samples.
Participants: A total of 1086 women with either breast or ovarian cancer.
Main outcome measure: The detection of sequence variation in patients' DNA samples that is not found in sets of control samples.
Results: BRCA1 mutations have now been identified in a total of 80 patient samples. Thirty-eight distinct mutations were found among 63 mutations identified through a complete screen of the BRCA1 gene. Three specific mutations appeared relatively common, occurring eight, seven, and five times, respectively. When specific tests for the two most common mutations were performed in larger sets of samples, they were found in 17 additional patients. Mutations predicted to result in a truncated protein accounted for 86% of the mutations detected by complete screening.
Conclusions: The high frequency of protein-terminating mutations and the observation of many recurrent mutations found in a diverse set of samples could lead to a relatively simple diagnostic test for BRCA1 mutations. More data must be accumulated to address specifically the sensitivity and specificity of such a diagnostic testing procedure and to better estimate the age-specific risk for breast and ovarian cancer associated with such mutations.
Similar articles
- Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test.
De Benedetti VM, Radice P, Mondini P, Spatti G, Conti A, Illeni MT, Caligo MA, Cipollini G, Bevilaqua G, Pilotti S, Pierotti MA. De Benedetti VM, et al. Oncogene. 1996 Sep 19;13(6):1353-7. Oncogene. 1996. PMID: 8808710 - BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. Yazici H, et al. Br J Cancer. 2000 Sep;83(6):737-42. doi: 10.1054/bjoc.2000.1332. Br J Cancer. 2000. PMID: 10952777 Free PMC article. - High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B. Pohlreich P, et al. Breast Cancer Res. 2005;7(5):R728-36. doi: 10.1186/bcr1282. Epub 2005 Jul 19. Breast Cancer Res. 2005. PMID: 16168118 Free PMC article. - Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
Kuschel B, Lux MP, Goecke TO, Beckmann MW. Kuschel B, et al. Eur J Cancer Prev. 2000 Jun;9(3):139-50. Eur J Cancer Prev. 2000. PMID: 10954253 Review. - Mutations of the BRCA1 gene in human cancer.
Xu CF, Solomon E. Xu CF, et al. Semin Cancer Biol. 1996 Feb;7(1):33-40. doi: 10.1006/scbi.1996.0005. Semin Cancer Biol. 1996. PMID: 8695765 Review.
Cited by
- Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
Hayes F, Cayanan C, Barillà D, Monteiro AN. Hayes F, et al. Cancer Res. 2000 May 1;60(9):2411-8. Cancer Res. 2000. PMID: 10811118 Free PMC article. - Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: identification of three novel mutations and of two new polymorphisms.
Gasparini P, D'Agruma L, Pio de Cillis G, Balestrazzi P, Mingarelli R, Zelante L. Gasparini P, et al. Hum Genet. 1996 Apr;97(4):492-5. doi: 10.1007/BF02267073. Hum Genet. 1996. PMID: 8834249 - Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE. Neuhausen SL, et al. Am J Hum Genet. 1996 Feb;58(2):271-80. Am J Hum Genet. 1996. PMID: 8571953 Free PMC article. - Ovarian cysts in women receiving tamoxifen for breast cancer.
Mourits MJ, de Vries EG, Willemse PH, ten Hoor KA, Hollema H, Sluiter WJ, de Bruijn HW, van der Zee AG. Mourits MJ, et al. Br J Cancer. 1999 Apr;79(11-12):1761-4. doi: 10.1038/sj.bjc.6690280. Br J Cancer. 1999. PMID: 10206289 Free PMC article. - BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.
Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pagès S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Clough KB, Pouillart P, Bonaïti-Pellié C, Thomas G. Stoppa-Lyonnet D, et al. Am J Hum Genet. 1997 May;60(5):1021-30. Am J Hum Genet. 1997. PMID: 9150149 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous